As a result of our discovery that nucleolin is the likely target of novel aptamer oligonucleotides with strong antitumor activity, we have become interested in the role of this protein in cancer biology. We have proposed that the tumor-selective effects of these aptamers occur because certain nucleolin functions are more critical for the survival of transformed cells than for normal cells. Elevated levels of nucleolin are already known to be associated with malignant progression and poor clinical prognosis in a variety of cancers. However, because the best characterized functions of nucleolin involve ribosome biogenesis, it is commonly supposed that this relationship merely reflects the higher proliferative activity of malignant cells. For this reason, the functional role of nucleolin in cancer has not been extensively studied. The central hypothesis of this proposal is that rather than being simply a marker for cancer, nucleolin overexpression actively contributes to the process of malignant transformation. This postulate is based in part on a number of recent studies that have identified new functions for nucleolin, many of which could potentially promote the development, survival, or progression of the malignant phenotype. In addition, preliminary data indicate that expression of antisense nucleolin mRNA in Hela tumor cells leads to reduced proliferation and suppression of anchorage-independent growth, whereas HeLa cell lines overexpressing nucleolin exhibit a more aggressive phenotype compared to wild type cells.
The aim of the proposal is to test the hypothesis that overexpression of nucleolin can cause neoplastic transformation of normal cells in vitro and in vivo, This will be achieved by creating NIH3T3-derived cell lines with stable high level expression of nucleolin and generating transgenic mice that have prostate-targeted overexpression of nucleolin. Cell lines will be analyzed for standard features of malignancy such as altered morphology, increased proliferation, anchorage-independent growth, decreased sensitivity to apoptotic stimuli, enhanced migration, and tumorigenicity in nude mice. Transgenic mice will be examined histologically for malignant or pre-malignant changes of the prostate. Success in demonstrating that nucleolin overexpression functionally contributes to malignant transformation would open up new avenues for exploration in cancer research and firmly establish nucleolin as a novel target for therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA104230-01A1
Application #
6826563
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Perry, Mary Ellen
Project Start
2004-08-06
Project End
2006-07-31
Budget Start
2004-08-06
Budget End
2005-07-31
Support Year
1
Fiscal Year
2004
Total Cost
$132,300
Indirect Cost
Name
University of Louisville
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
057588857
City
Louisville
State
KY
Country
United States
Zip Code
40292
Bates, Paula J; Reyes-Reyes, Elsa M; Malik, Mohammad T et al. (2017) G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms. Biochim Biophys Acta Gen Subj 1861:1414-1428
Bates, Paula J; Laber, Damian A; Miller, Donald M et al. (2009) Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86:151-64